Postauthorisation Safety Study (PASS) of Avatrombopag and Haematological Malignancies in Patients With Primary Immune Thrombocytopaenia First published 30/09/2024 Last updated 18/12/2024 EU PAS number:EUPAS1000000315 Study Planned